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A B S T R A C T
In this work, a genotype-phenotype survey of a highly diversified Pseudomonas aeruginosa collection was con-
ducted, aiming to detail pathogen-associated scenarios that clinicians face nowadays. Genetic relation based on
RAPD-PCR of 705 isolates, retrieved from 424 patients and several clinical contexts, reported an almost isolate-
specific molecular-pattern. Pneumonia-associated isolates HB13 and HB15, clustered in the same RAPD-PCR
group, were selected to evaluate the genomic background underlying their contrasting antibiotic resistance and
virulence. The HB13 genome harbors antibiotic-inactivating enzymes-coding genes (e.g. aac(3)-Ia, arr, blaVIM-2)
and single-nucleotide variations (SNVs) in antibiotic targets, likely accounting for its pan-resistance, whereas
HB15 susceptibility correlated to predicted dysfunctional alleles. Isolate HB13 showed the unprecedented rhl-
cluster absence and variations in other pathogen competitiveness contributors. Conversely, HB15 genome
comprises exoenzyme-coding genes and SNVs linked to increased virulence. Secretome analysis identified sig-
natures features with unknown function as potential novel pathogenic (e.g. a MATE-protein in HB13, a protease
in HB15) and antibiotic resistance (a HlyD-like secretion protein in HB13) determinants. Detection of active
prophages, proteases (including protease IV and alkaline metalloproteinase), a porin and a peptidase in HB15
highlights the secreted arsenal likely essential for its virulent behavior. The presented phenotype-genome as-
sociation will contribute to the current knowledge on Pseudomonas aeruginosa pathogenomics.
1. Introduction
Pseudomonas aeruginosa is a versatile Gram-negative bacterium
widespread throughout the environment, known as a ubiquitous op-
portunistic pathogen able to cause both acute and chronic infections in
humans [1]. According to point-prevalence surveys carried out in USA,
Europe and Asia, P. aeruginosa has emerged as a leading cause of no-
socomial infections, being one of the primary agents to cause infections
in immunocompromised individuals and other highly vulnerable pa-
tients [2–4]. Infections are often associated with great morbidity and
mortality due to its wide spectrum resistance to antimicrobials. Ther-
apeutic options are becoming increasingly limited with the continued
emergence and spread of multidrug-resistant (MDR) strains, making it
one of the most problematic organisms to treat and eradicate from
hospital environment [5].
The advent of next-generation sequencing technologies prompted
the expansion of genome-based knowledge of P. aeruginosa strains as
several whole-genome projects have been completed and more are in
completion [6]. Pseudomonas aeruginosa genome is a mosaic of a con-
served core component, interrupted by combinations of strain-specific
blocks of genetic material, acquired by horizontal gene transfer (HGT)
events [7], that varies according to the evolutionary traits of each
isolate. HGT events play an important role in the evolution of pathogen
competitiveness and fitness, leading to a constant and unpredicted
fluctuation of the clinical outcome [8]. Genome-wide comparisons be-
tween strains enabled the large-scale detection of genetic variability
among isolates through identification of single-nucleotide variations
(SNVs) and insertions/deletions of bases (indels), considerably im-
proving the understanding of P. aeruginosa strain-specific physiology
towards distinct pathogenesis traits.
A collaboration set with a Portuguese Hospital towards the eluci-
dation of genotypic and phenotypic variability among P. aeruginosa
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clinical isolates, aimed to rouse a holistic research approach to provide
relevant information and tools for the clinicians to circumvent the
multi-resistance and pathogenicity phenomena in P. aeruginosa isolates.
Currently, our Pseudomonas aeruginosa collection contains 705 isolates,
seasonally collected from diverse clinical contexts, to provide a com-
prehensive epidemiological and genotypic categorization, contributing
to an increased effectiveness of surveillance systems, outbreak detec-
tion and clinical treatment. To accomplish this task, we have tested and
validated a PCR-based genotypic pipeline, as it is a fast and cost-ef-
fective method used for the primary screening of large collections [9].
In this work, from a representative subpanel further assayed for
phenotypic comparison, two pneumonia-associated isolates were se-
lected for high-throughput sequencing to identify the genomic basis
associated with the distinct phenotypes, using both MiSeq and Genome
Analyzer IIx [10] from Illumina. This is, to our knowledge, the first
epidemiological report of a diverse collection of Portuguese Pseudo-
monas aeruginosa clinical isolates coupling genotyping, phenotyping
and genomic approaches.
2. Materials and methods
2.1. Pseudomonas aeruginosa isolates
A Portuguese Hospital setting (Hospital de Braga) provided 705
Pseudomonas aeruginosa isolates retrieved from different sources during
March and June 2010–2014, upon approval by the Hospital Bioethics
Commission. Clinical isolates were obtained from different tissues/
fluids of 424 anonymous patients during routine clinical diagnostics
practices, at the hospital pathology department, in accordance with
approved guidelines. Information regarding source, hospital depart-
ment, clinical context, date of isolation, patient age and gender was
registered for each isolate. For comparison purposes, P. aeruginosa re-
ference strain PAO1 was used, as it is the most used P. aeruginosa la-
boratory strain, allowing comparison to other studies.
2.2. Diversity analysis by a standardized PCR-based genotypic pipeline
After optimization (Supplementary Material A), a standardized
RAPD-PCR-based genotypic pipeline, resorting to open access bioin-
formatic tools, was implemented. To standardize PCR amplifications
over time, in each gel at least two lanes with molecular weight stan-
dards were loaded for an improved molecular weight approximation,
along with a negative control (without DNA), and an amplification of
the same reference isolate, in order to verify the obtained pattern. Every
isolate was genotyped at least three times to confirm pattern-profile
reproducibility.
RAPD-PCR groups were determined applying a similarity threshold
to the clustered collection, and their representativeness and epidemio-
logical frequency distribution throughout the years assessed. Results
were explored associating groups to specific epidemiological profiles, to
determine variability within isolates.
2.3. Genotype-phenotype correlation of a Pseudomonas aeruginosa
subpanel
A panel of six clinical isolates (HB3, HB4, HB5, HB6, HB13, and
HB15) and the Pseudomonas aeruginosa reference strain PAO1 were
chosen for phenotype characterization: antibiotic susceptibility, moti-
lity, biofilm formation and pyocyanin production (Supplementary
Material A). Extracellular protein content was assayed for the two
isolates selected for genome sequencing.
2.4. Next-generation genome sequencing
Genomic DNA from a pan-resistant (resistant to all antibiotics
tested) P. aeruginosa, isolate HB13, and a susceptible P. aeruginosa,
isolate HB15, was extracted and purified using the Wizard Genomic
Purification Kit (Promega). Samples were processed according to
Illumina instructions generating pair-ended libraries, sequenced using
the Illumina MiSeq system (2x250 bp) at Yale Center for Genomic
Analysis. Supplementary Material A details the followed pipeline for
genome assembly, annotation and analysis. The Whole Genome
Shotgun projects of Pseudomonas aeruginosa HB13 and HB15 have been
deposited at EMBL/GenBank under the accessions AEVV00000000 and
AEVW00000000, respectively. The versions here described are
AEVV00000000.3 and AEVW00000000.3.
As antibiotic resistance and virulence greatly affect patient condi-
tion following infection, a detailed genomic contextualization was
carried out focusing on P. aeruginosa genes related to resistance and
virulence determinants, according to VFDB (Virulence Factors of
Pathogenic Bacteria Database [11]), PHIDIAS (Victors Virulence Fac-
tors; http://www.phidias.us/victors), PseudoCAP [6] and CARD
(Comprehensive Antibiotic Resistance Database [12]). This analysis
included genome comparison, identification of distinctive genome traits
and SNVs and/or indels in these determinants.
2.5. Extracellular peptide mass fingerprinting
Cell-free P. aeruginosa HB13 and HB15 supernatants were collected
for protein extraction and identification: exponential phase (4 h), early
stationary phase (8 h), late stationary phase (12 h) and dead zone
(20 h). Supplementary Material A contains the detailed protocol,
parameters and in silico tools used for peptide identification and ana-
lysis.
As we wanted to analyze the P. aeruginosa secretome (i.e. complete
set of secreted proteins), identified proteins with predicted cytoplasmic
localization were disregarded if no signal peptide cleavage site was
identified. These cytoplasmic proteins are likely contaminants, never-
theless, natural P. aeruginosa autolysis could lead to these protein re-
lease or even secretion by non-traditional pathways.
3. Results
3.1. Epidemiological and genetic diversity of the Pseudomonas aeruginosa
collection
This study provides an epidemiological overview of P. aeruginosa
infections in a Portuguese Hospital setting coupled to genotypic cate-
gorization of 705 clinical isolates collected from a variety of infection
loci, clinical context, hospital department and age groups from 424
patients (Fig. 1, Supplementary Table S1).
Regarding the infection context, about 49% (n=343) of isolates
were collected from multi-infected loci, predominantly with
Enterococcus faecalis, Escherichia coli, Staphylococcus aureus and
Klebsiella pneumoniae (Fig. 1), posing additional clinical challenges in
the eradication of infection focus. Isolates were categorized according
to antimicrobial susceptibility as MDR (resistant to three or more an-
tibiotic classes) and susceptible (no remarkable antibiotic resistance),
classifying 28% as MDR isolates (n= 194, Fig. 1), from which 11%
(n= 21) were classified as PDR (pan-resistant; generalized resistance).
The frequency of the P. aeruginosa MDR phenotype in Portuguese
Hospitals is higher than those reported in Europe or worldwide. Ac-
cording to the ATLAS (Antimicrobial Testing Leadership And Surveil-
lance) database from Pfizer (https://atlas-surveillance.com/), in the
same timeframe as our collection (2010–2014) and considering re-
sistance to the assayed antibiotic classes, 13 and 14% of reported P.
aeruginosa evidenced the MDR phenotype worldwide and in Europe,
respectively, comparing to the 23% registered for Portugal. As men-
tioned by Castañeda-Montes et al. [13], this observed higher resistance
could be owed to the socio-political context of the country, accounting
for the national effort to improve antibiotic stewardship.
Epidemiological studies are fundamental to public health, mainly in
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microbiological control and preventive medicine, thus, we further ca-
tegorized the observed heterogeneity of Pseudomonas aeruginosa clinical
contexts. In this context, RAPD-PCR and combination of the Dice dis-
similarity coefficient with the hierarchical clustering method UPGMA
were tested and validated as the best strategy for a genotypic
categorization of the P. aeruginosa collection (Supplementary Material
B), evidencing greater discriminatory power than other data analysis
approaches, while clustering putative clonal isolates. RAPD-PCR was
the technique chosen for genotypic characterization in our research
since it is simple, inexpensive and rapid, less labor intensive and
therefore more amenable to high-throughput screenings, allowing
continuous monitoring of clinical isolates throughout the years.
Applying this PCR-based pipeline to the P. aeruginosa collection and
considering a similarity threshold of 80%, we observe a ratio of 0.94
genotypic profile per isolate (666 unique genotypic patterns for 705
samples) and a genetic relation ranging between 0.00 and 0.77, sus-
taining an apparent great genetic variation. Most studies state a lesser
distance, as the report of 35 genotypes for 385 isolates (ratio of 0.09)
[14] and 31 genotypes for 48 isolates (ratio of 0.65) [15], however,
they focus on specific isolates groups, such as ones recovered from CF-
patients and not a diverse collection as ours.
In order to obtain a workable number of RAPD-PCR groups, a less
conservative similarity threshold of 30%, thus considering an apparent
genetic variability of 0.70, clusters the collection into 14 groups (Fig. 2)
with distinct representativeness over the years and among multi-in-
fection context and MDR phenotype, evidencing the great heterogeneity
of P. aeruginosa population (Fig. 3, Supplementary Table S1). No ob-
vious correlation of a RAPD-PCR group with a specific phenotype or
source suggests a highly diversified non-nosocomial origin of infection
for most clinical cases in this Portuguese Hospital setting, rather than
epidemic or prevalent nosocomial cause, which sustains the well-de-
scribed Pseudomonas aeruginosa ubiquitous character [1,16].
3.2. Correlating genotype-phenotype in a Pseudomonas aeruginosa subpanel
Understanding the reported P. aeruginosa individuality based on
distinct genetic patterns is critical for correct infection diagnosis and
treatment since clinicians rely heavily on predicting phenotypes from
genetic variations [17]. In this context, a subpanel of clinical isolates
and P. aeruginosa PAO1 as a reference strain were assayed for common
virulence-associated traits, to verify a possible genotype-phenotype
link. This subpanel comprised two same-source isolates genotypically
clustered in the same RAPD-PCR group and one genotypically distant
same-source isolate, from the two registered main sources: urine (HB3,
HB5, HB6) and sputum (HB4, HB13, HB15) (Table 1). Thus, with this
subpanel we assayed six isolates previously clustered in 4 groups, re-
presenting a ratio of 0.67 genotypic profiles per isolate, with an overall
apparent genetic variability of 0.75. Antibiotic resistance profiles
ranged from pan-susceptibility (HB4, HB6, HB15), to a PDR phenotype
(HB13).
Under the tested conditions, comparing to P. aeruginosa PAO1, the
panel of isolates showed distinct motility profiles (Table 1). Isolate HB4
presented the largest flagella-mediated swimming halo and isolate
HB15 showed the smallest. Ability to swarm was very asymmetric and,
as all isolates displayed flagella-mediated swimming, differences in
swarming may be associated with diversity in type IV pili biogenesis
[18]. Concomitantly, isolates HB5 and HB6 exhibited the highest
twitching motility halos and the highest swarming ability, whereas the
other isolates showed reduced or lacked this kind of motility. Motility
influences biofilm formation at different stages and at initial stages,
motility is indeed crucial for biofilm architecture [19]. When com-
paring to P. aeruginosa PAO1, isolates HB5 and HB6 displayed higher
biofilm production, which correlates to longer diameters detected in
type-IV pili-dependent swarming and twitching assays. Pyocyanin is a
blue pigment secreted by P. aeruginosa, described to act as virulence
factor in infection [20]. Isolates HB3, HB4, HB15 and PAO1 (with no
significant differences) had highest pyocyanin levels whereas isolate
HB13 registered an undetectable amount of blue pigment, even after
longer growth periods. We normalized and compiled these phenotypic
traits in a multivariate matrix to compare with the genotype-based
clustering (Fig. 4). The differential isolate grouping is easily observed
Fig. 1. Overall distribution of Pseudomonas aeruginosa isolates from 424
patients of a Portuguese Hospital setting, during March and June
2010–2014, according to age group and gender of the infected patient,
type of infection and antibiotic resistance profile. Main co-inhabitant bac-
teria, when in a multi-infection context, as well as distribution of multidrug-
resistant isolates throughout the years are represented. P. aeruginosa isolates
assayed for resistance to following antibiotics: ceftazidime, meropenem, pi-
peracillin with tazobactam, tobramycin, amikacin, gentamicin and cipro-
floxacin. Multidrug-resistance (MDR) phenotype attributed if resistant to three
or more antibiotics classes.
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and the calculated correlation value of −0.328 suggests a lack of col-
linearity between the two trees, thus supporting P. aeruginosa hetero-
geneity.
The number of P. aeruginosa clinical isolates associated with re-
spiratory infections corresponds to 29% of all Portuguese isolates, being
pneumonia the main representative. In this study, isolates HB13 and
HB15, clustered in the same RAPD-PCR group, out-performed others
respectively concerning pan-resistance and virulence indicators. Having
in mind the distinctive traits evidenced by isolates causing similar in-
fections and the significant clinical impact, as the genotype dis-
crimination was insufficient, isolates HB13 and HB15, both collected
from the sputum of pneumonia-diagnosed patients and belonging to
group L, were selected to determine their genomic background and its
relationship with the registered phenotypic differences.
3.3. Pseudomonas aeruginosa HB13 and HB15 comparative genomics
P. aeruginosa HB13 and HB15 were sequenced with Illumina MiSeq
technology and Supplementary Material A outlines the assembly pipe-
line. Scaffolding and gap-closure were performed using the MiSeq da-
tasets here obtained (2x250 bp) and Illumina GAIIx 2x50 bp datasets
previously reported [10]. The draft genome assembly was obtained
after automated assembly improvement and manual curation. The
isolate HB13 draft genome comprised 22 scaffolds (24 contigs) with
6,534,891 bp and 332 unknown bases (Ns), whereas the isolate HB15
draft genome comprised 19 scaffolds (20 contigs) with 6,643,276 bp
and 654 Ns. This resulted in great contiguity and overall assembly
quality improvement over the previously reported assembly.
Despite not being from a respiratory infection context, given that
our data showed lack of genotypic pattern and source relation, P. aer-
uginosa PAO1 was selected as reference strain for comparative analysis
(Fig. 5a) [21]. Freschi et al. [22] reported the division of 389 P. aeru-
ginosa strains into three major groups, based on the SNPs within the
core genome. Following this phylogenetic analysis, isolate HB13 was
included in the same group as the P. aeruginosa PAO1, yet genetically
closer to the reference strain LESB58, while isolate HB15 was included
in the same group as P. aeruginosa PA14 (Fig. 5b). This corroborates the
association obtained in this study of these two isolates with the re-
ference strains LESB58 and PA14 (Supplementary Material B). How-
ever, since the same study reported that the conserved regions among
all isolates represented 17.5% of the average P. aeruginosa genome size
[22], our analysis was primarily focused on genomic features with
distinct distribution.
The comparison of gene organization of isolates HB13 and HB15
with P. aeruginosa PAO1 reference genome allowed the identification of
distinct distribution of 90 features related to antibiotic resistance and
virulence in both isolates (10 and 80 genes, respectively; Fig. 6,
Supplementary Table S2). Genetic loci associated with replacement is-
lands (flagellin - RGP9; lipopolysaccharide O-antigen - RGP31; pilin -
RGP60; pyoverdine biosynthesis and posttranslational modification -
RGP73) were disregarded as they are under diversifying selection and
are highly variable between strains [23]. In P. aeruginosa HB13, 72% of
Fig. 2. Distribution of the Pseudomonas aeruginosa clinical isolates and reference strains by the 14 RAPD-PCR groups. Color represents distinct groups
considering a genetic relation h value of 0.70 (similarity of 30%).
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virulence determinants and 20% of antibiotic resistance features are
missing, whereas isolate HB15 respectively lacks 16% and 80% of these
determinants.
P. aeruginosa HB13 is missing several virulence-associated genetic
features, such as those encoding for the transcriptional regulators
ptxRS, that enhances the production of exotoxin A [24], and the rhlRI
cluster, a key component of one P. aeruginosa Quorum-Sensing (QS)
system. QS systems regulate, in a cell-density-dependent manner, sev-
eral P. aeruginosa physiological traits, mainly related to virulence [25].
P. aeruginosa HB13 genome also lacks the AraC-type transcriptional
regulator vqsM, a global regulator essential for P. aeruginosa QS and
virulence modulation. Inactivation is related to lack of proteolytic ac-
tivity owing to attenuated AHL production [26], pathogenesis loss and
higher antibiotic resistance [27]. Moreover, the amb five-gene cluster
responsible for the biosynthesis of L-2-amino-4-methoxy-trans-3-bute-
noic acid, a potent toxin against prokaryotes and eukaryotes with re-
ported contribution to P. aeruginosa pathogenic potential [28], is also
absent in isolate HB13. P. aeruginosa also secretes several exoenzymes
Fig. 3. Epidemiological overview of Pseudomonas aeruginosa isolates from 424 patients of a Portuguese Hospital setting. Representativeness of each RAPD-
PCR groups presented as percentage of total P. aeruginosa isolates (705 plus 3 reference strains). Relative frequency of clinical isolates in RAPD-PCR groups among
multi-infection context, MDR phenotype, isolation source, clinical context and hospital department, presented as group percentage. Absolute frequency for each
metadata, detailed in Supplementary Table S1, is indicated.
a Others contains all sources and departments that individually contributed with less than 1% of the total isolates collected. b Respiratory infections includes every
reported medical condition associated with respiratory tract, such as pneumonia and cystic fibrosis. Wound infections comprises every case of reported acute, surgical
and chronic wounds, including ulcers. Routine evaluation corresponds to isolations in regular hospital visits, or not associated with a medical condition.
Table 1
Phenotypic characterization of a Pseudomonas aeruginosa subpanel from a Portuguese Hospital setting. This subpanel was assayed for antibiotic susceptibility,
metallo-β-lactamases, motility, biofilm formation and pyocyanin production (Supplementary Material A). RAPD-PCR group is the classification according to gen-
otypic clustering. Data from motility, biofilm and pyocyanin assays is shown as fold change ratio between values measured for each isolate and those of P. aeruginosa
reference strain PAO1.
Isolates HB3 HB4 HB5 HB6 HB13 HB15
Source Urine Sputum Urine Urine Sputum Sputum
Clinical context Sepsis Pneumonia Urinary infection Urinary infection Pneumonia Pneumonia
RAPD-PCR group J H N N L L
AB profile
CAZ S S S S R S
MEM R S S S R S
TZP R S S S R S
TOB S S R S R S
AMK R S R S R S
GEN R S R S R S
CIP S S R S R S
MBL – – – – + –
Motility
Swimming 0.7 1.2 0.9 0.8 0.6 0.3
Swarming 0.7 0.8 2.1 1.4 0.7 0.9
Twitching ND ND 4.5 4.9 ND 1.1
Biofilm 1.1 0.6 3.6 1.7 1.3 1.3
Pyocyanin 1.2 1.0 0.5 0.4 ND 1.3
AB, Antibiotic; CAZ, Ceftazidime; MEM, Meropenem; TZP, Piperacillin/Tazobactam; TOB, Tobramycin; AMK, Amikacin; GEN, Gentamicin; CIP, Ciprofloxacin; S,
susceptible; R, resistant.
MBL, metallo-β-lactamases; +, MBL detected; –, MBL not detected; ND, not detected.
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that target host cells (ExoU, ExoS, ExoT, and ExoY), with differential
effects in pathogenesis. ExoY is reported to have a minor role in pa-
thogenesis [29], whereas ExoU is often associated with virulent P.
aeruginosa strains and acute infections [30]. Furthermore, exoU deletion
significantly reduces overall virulence and impairs pathogenesis de-
velopment in the mice lung [31]. Studies on ExoS and ExoT report a
lesser effect on virulence [32,33]. P. aeruginosa HB13 harbors only exoS
and exoT genes, whereas P. aeruginosa HB15 harbors exoU, exoT and
exoY genes.
We analyzed whether the genomic constitution of isolates HB13 and
HB15 correlated with their antibiotic resistant phenotype by looking to
antibiotic-resistant features, and we showed this to be the case, since
the genome of isolate HB15 is, apparently, missing some loci, as the
gene aac(3)-Ia, which codes for an aminoglycoside-modifying enzyme,
and the aminoglycoside response regulator gene arr. In contrast, isolate
HB13 evidenced an enrichment in efflux pumps and other antibiotic
resistance-associated features, such as VIM-2, the most-reported
worldwide extended spectrum metallo-β-lactamase [34], which, see-
mingly, confers pan-resistance to β-lactams and the sulfonamides
resistance gene sul1 [35]. The multidrug resistance phenotype of isolate
HB13 had been previously hinted by its allelic sequence type [10]. P.
aeruginosa HB13 is a representative of ST175, a widely disseminated
type associated with multidrug resistance, while P. aeruginosa HB15
belongs to the ST560, a rare allelic sequence type not specific to the
human host, also associated with animal and environmental strains
[36,37]. ST175 has been reported as an internationally distributed VIM-
2 MBL-producing epidemic lineage [38,39] and as one of the most
successful high-risk clones, grouping the majority of MDR P. aeruginosa
strains [40], sustaining our in silico analysis.
While data relevant to antibiotic resistance and virulence is rapidly
expanding, a considerable part of microbial genomes is still associated
with proteins with hypothetical or unknown function. As this com-
parative analysis relies on curated databases of known determinants
and pathogenicity is both combinatorial and multifactorial [41], cur-
rently unknown factors cannot be ruled out but would not be identified
by this approach. Therefore, aiming to provide new insights into P.
aeruginosa pathogenicity, signature features of isolates HB13 and HB15,
i.e. present only on the respective isolate genome, were analyzed (data
not shown). We predicted protein domains for hits with unknown or
putative function resorting to in silico tools to identify new potential
determinants of the observed phenotypic variation. This analysis pre-
dicted domains linked to antibiotic resistance for two signature features
in isolate HB13: a MATE domain in PA13_1001085, and a metallo-β-
lactamase domain in PA13_1011590. The role of metallo-β-lactamases
has been discussed and similarly, members of the multidrug and toxin
extrusion (MATE) family are also associated with MDR phenotype,
functioning as drug/Na+ antiporters [42]. Moreover, in isolate HB15
three hypothetical proteins putatively hold virulence-associated do-
mains: a nucleotidyltransferase AbiEii toxin in PA15_0312500; a tran-
scriptional regulator AbiEi antitoxin in PA15_0312505; and a peptidase
M91 in PA15_0330735. Together, the first two constitute a type IV
bacteriostatic toxin-antitoxin innate immunity bacterial abortive in-
fection (Abi) system [43]. Abi systems provide bacterial population
resistance to phage infection [44] and from our analysis, the only
completely assembled Pseudomonas genome possessing this system is
Pseudomonas stutzeri SLG510A3-8 [45]. Peptidase M91 is a zinc me-
tallopeptidases family which members are effector proteins that aid in
inactivation of inflammatory response [46].
3.3.1. SNVs and indels in Pseudomonas aeruginosa HB13 and HB15 core
genome
The profile of nucleotide changes may unravel additional genetic
signatures of strain-specific microevolution driven by selective forces
intrinsic to the colonized niche, eventually leading to accumulation of
adaptive mutations [47]. Aiming to contextualize variation associated
with antibiotic resistance and virulence, we focused this analysis on
these determinants, identifying for isolate HB13, sequence alterations
Fig. 4. Clustering of a Pseudomonas aeruginosa subpanel from a Portuguese Hospital setting. Dendrogram constructed based on genotypic and phenotypic
relation, applying the previously described pipelines.
Fig. 5. Gene organization of Pseudomonas aeruginosa HB13 and HB15. (a)
Graphical representation of BLAST-based genome comparison using
CGView Comparison Tool [21]. Outermost circle depicts ORFs on the positive
and negative strand. Innermost circles represent GC content and GC skew. (1) P.
aeruginosa PAO1; (2) P. aeruginosa HB15; and (3) P. aeruginosa HB13. (b)
Adaptation of the maximum likelihood tree of 389 Pseudomonas aerugi-
nosa genomes based on SNPs within the core genome, reported by Freschi
et al. [22]. Number of strains for each of the three major groups (group 1: blue,
group 2: orange and group 3: green) is shown. Main P. aeruginosa reference
strains and the two clinical isolates described in this study are highlighted.
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in 63 genes related to resistance and virulence altered, including 10
non-synonymous SNVs affecting protein function (Supplementary Table
S3). A lesser virulent ability of P. aeruginosa HB13 was supported by
intolerant SNVs in aprF and aprX, suggesting a deficient secretion of
alkaline protease [48], known to enhance ability of tissue invasion and
interfere with host defense mechanisms [49] and in aaaA, where mu-
tations significantly attenuate pathogenicity in the chronic wound
model [50]. Regarding antibiotic resistance, predicted intolerant SNVs
might also contribute to the isolate HB13 PDR-phenotype, such as the
variation in the subunit B of DNA gyrase (gyrB), described in other
fluoroquinolone-resistant P. aeruginosa isolates as a resistance de-
terminant [51].
P. aeruginosa HB15 harbors in 46 genes linked to resistance and
virulence, 6 SNVs predicted to affect protein function and 7 indels
(Supplementary Table S4). From the sequence alterations detected, the
SNV in the aminopeptidase-coding gene phpA may contribute to an
increased expression of virulence-associated alginate biosynthetic genes
[52]. The observed susceptible phenotype of isolate HB15 might also be
supported by variations in three specific gene products. The organic
solvent tolerance protein OstA precursor is suggested to determine
sensitivity to organic solvents, membrane permeability and suscept-
ibility to antibiotics [53]. ArmZ, which interacts with MexZ, the ne-
gative-regulator of MexXY efflux [54], is unable to derepress MexXY-
related antibiotic resistance when dysfunctional, contributing to sus-
ceptibility to aminoglycosides. Furthermore, the membrane protein
OpdE exhibited increased expression in resistant isolates [55] and
mutation was associated with susceptibility to several antibiotics [56].
Further molecular approaches are necessary to evaluate the effect of
these events in genes linked to improved resistance and virulence, to-
wards circumventing P. aeruginosa multi-resistance and pathogenicity.
3.4. Pseudomonas aeruginosa HB13 and HB15 pathogenic potential
Despite all advantages of in silico tools, due to unavailability of
experimental validations, there is a fair degree of uncertainty associated
with its predictions. Therefore, in silico predicted avirulent PDR-phe-
notype of isolate HB13 and virulent antibiotic-susceptible phenotype of
HB15 were analyzed by MALDI-TOF identification of extracellular
protein content (Fig. 7, Table 2).
The main identified function-known proteins in PDR isolate HB13
supernatants corresponded to the secreted protease elastase LasB after
8 h of growth and in both exponential and stationary phases, the me-
tallo-β-lactamase VIM-2, previously identified as a P. aeruginosa HB13
signature feature (Fig. 6). Elastase LasB is a metalloprotease able to
induce tissue damage [57] and involved in degradation of host tissue-
modelling enzymes [58]. Metallo-β-lactamases enzymes secretion
causes P. aeruginosa antibiotic resistance [59], supporting in silico
predictions and the evidenced isolate HB13 resistance to β-lactams.
Mass spectrometry of isolate HB15 supernatants detected several
protein-degrading enzymes, such as an alkaline metalloproteinase
precursor and a putative peptidase (PA15_0315610), within the ex-
ponential growth phase. P. aeruginosa HB15 evidenced proteolytic ac-
tivity at early stages and an elastase LasB and protease IV enrichment
over time. These extracellular protein/peptide-degrading enzymes
produced by isolate HB15, namely elastase LasB, protease IV and al-
kaline metalloproteinase, are well-known P. aeruginosa virulence fac-
tors, secreted to assist bacterial invasiveness [60,61].
Blast analysis of an aminopeptidase, secreted by isolate HB13
(PA13_1011705) at 12 h of growth, and by isolate HB15
(PA15_0303145) at 8 h, 12 h and 20 h of growth, showed 100% identity
to a leucine aminopeptidase PaAP, present in several other P. aerugi-
nosa, with reported role in pathogenesis [62] and possibly contributing
to infection persistence [63]. Despite both isolates being able to secrete
it, P. aeruginosa HB15 did it from the early stationary phase to the dead
zone, suggesting an earlier and more permanent virulent potential. Both
P. aeruginosa HB13 and H15 also secreted a hypothetical protein
(PA13_1021130, PA15_0314610) homologous to IMPa, an im-
munomodulating metalloprotease with suggested role in P. aeruginosa
persistence and pathogenesis [64].
We identified a putative membrane protein (PA13_1009415) in
isolate HB13 whose domain prediction associated with HlyD-like se-
cretion proteins, particularly a component of a type I secretion system
anchored in the cytoplasmic membrane [65], whose localization was
confirmed by in silico analysis. This protein belongs to a large family of
membrane fusion proteins involved in export of different compounds,
including drug molecules [66], as does the MexA in P. aeruginosa [67],
thus associating this hit with antibiotic resistance.
Isolate HB15 secreted a putative porin (PA15_0327485) predicted to
Fig. 6. Comparison of genomic content of Pseudomonas aeruginosa isolates HB13 and HB15 and reference strain PAO1. Heat map representation of genes
associated with antibiotic resistance and virulence, with a distinct distribution in isolates HB13 and HB15 and reference strain P. aeruginosa PAO1. Genes associated
with replacement islands were not considered. Black represents when a CDS is present in a specified genome, whereas white symbolizes gene absence in the specified
genome. Supplementary Table S2 identifies each corresponding locus_tag.
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be associated with OprF, a major outer membrane protein conserved
across clinical isolates. Studies describe it as a host immune system
sensor, modulating QS to enhance virulence when the bacteria are in
contact with host cells [68], being required for expression of P. aeru-
ginosa full virulence [69]. After 4 h of growth, isolate HB15 also se-
creted a putative peptidase (PA15_0315610), whose blast analysis in-
dicated homology to proteins mainly belonging to other Pseudomonas
species, some annotated as peptidase M16 (Supplementary Fig. S1).
Accordingly, in silico tools predicted two peptidase M16 domains, one
active and other inactive. Peptidase M16 is known to hold its substrate
as a clamp, with an active peptidase domain and a C-terminal inactive
domain [70], thus hinting a functional protein secretion by isolate
HB15. These metalloproteases are important for several biological
processes and its substrates are involved in human disease pathogenesis
[71].
4. Discussion
Albeit the high number of diagnosed infections, our data suggests an
almost unique molecular fingerprint for each clinical isolate. This ge-
netic singularity may reflect P. aeruginosa success in human infections,
with repercussions in patient segregation policies and therapeutic
strategies. High heterogeneity of MDR (including PDR and colistin-re-
sistant) isolates indicates that acquisition of these traits may not be
more favorable to occur in genotypically close isolates, but rather a
widespread ability. Inadequate procedures towards infection control
and eradication policies were signaled by a radical change in resistance
profile, towards MDR (e.g. susceptible isolate HB314 and MDR isolate
HB334, collected from same-patient sputum within one month), which
lead to bacterial survival and adaptation to therapeutic strategies.
These are alarming findings given the inability to relate epidemiology
Fig. 7. Extracellular protein profiles of Pseudomonas aeruginosa isolates HB13 and HB15. Several time points were collected from cultures of P. aeruginosa
isolates HB13 (a) and HB15 (b): exponential phase (4 h), early stationary phase (8 h), late stationary phase (12 h) and dead zone (20 h). Correspondence of gel
coordinates and protein ID available at Table 2 and Supplementary Table S5.
Table 2
Main identified proteins on LB-grown supernatant of Pseudomonas aeruginosa isolates HB13 and HB15, by MALDI-TOF mass spectrometry. Full list of
identified proteins and corresponding scores is available at Supplementary Table S5.
Locus_Tag Product Predicted domains and superfamiliesa SPb Localizationc TPd
PA13_1004255 Elastase LasB – + E 8 h, 12 h, 20 h (a4, a8, a13)
PA13_1009415 Putative membrane protein HlyD-like secretion proteins
RND eflux pump family, MFP
+ CM 20 h (a11)
PA13_1011705 Aminopeptidase – + E 12 h (a7)
PA13_1021130 Hypothetical protein Peptidase M60; DUF3712 + OM 4 h, 8 h, 20 h (a1, a3, a10)
PA13_1028635 Metallo-β-lactamase VIM-2 subclass B1 – + U 4 h, 12 h (a2, a9)
PA15_0303145 Aminopeptidase – + E 8 h, 12 h, 20 h (b7, b19, b27)
PA15_0307120 Elastase LasB – + E 8 h, 12 h, 20 h (b12, b18, b25)
PA15_0309435 Protease IV – + E 8 h, 12 h, 20 h (b13, b22, b32)
PA15_0310815 Alkaline metalloproteinase precursor AprA – + E 4 h (b1)
PA15_0314315 Phage tail length tape measure protein – – OM 8 h (b4)
PA15_0314335 Bacteriophage tail protein Phage tail sheath protein subtilisin-like domain – U 8 h, 12 h, 20 h (b9, b21, b29)
PA15_0314340 Bacteriophage protein Phage tail-collar fibre protein + E 8 h, 12 h (b5, b17)
PA15_0314610 Hypothetical protein Peptidase M60; DUF3712 + OM 8 h, 12 h, 20 h (b3, b16, b24)
PA15_0315610 Putative peptidase Peptidase M16, N-terminal
Peptidase M16 inactive domain, C-terminal
+ U 4 h (b2)
PA15_0327485 Putative porin OprF membrane domain + OM 8 h (b11)
a Prediction of protein domains according to InterPro, HMMER, CDD for hits with unknown or putative function.
b Prediction of signal peptide (SP) cleavage sites presence according to SignalP 4.1, TargetP 1.1 and TatP 1.0: , absence; +, presence.
c Prediction of cellular localization according to PSORTb, Gneg-mPLoc, SOSUIGramN, CELLO2GO: E, extracellular; OM, outer membrane; P, periplasmic; CM,
cytoplasmic membrane; F, flagellar; U, unknown.
d TP, time point. The corresponding gel coordinate from Fig. 5 is indicated in parentheses.
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to genotypic profiles, sustaining the need for stricter infection control
and effective antibiotic stewardship measures in hospital settings for
better patient management. To further understand and evaluate the
clinical consequences of such genetic diversity among P. aeruginosa,
high-throughput approaches as those employed by the international
Pseudomonas aeruginosa consortium [22] are mandatory. Expectedly,
these efforts will contribute to the development of effective molecular
biomarker-based tools for fast discrimination and diagnosis of in-
dividual P. aeruginosa isolates.
Ultimately, our work highlighted the genomic diversification oc-
curring within P. aeruginosa strains and hinted that it might reflect a
distinctive pathogenic behavior. Accordingly, apparent absence of
virulence determinant genes and the exoenzyme-coding genes profile in
P. aeruginosa HB13 suggests decreased ability to deploy extensive host
damage, whereas P. aeruginosa HB15, putatively, possesses an arsenal
that allows it to have a virulent behavior. Negative mutants in QS
systems have reduced cytotoxicity due to defective signaling and re-
duced release of extracellular virulence factors [72]. However, these
reported negative mutants display point mutations and not complete
cluster deletions as deduced for the genomic analysis of isolate HB13.
The rhlRI system directly activates the rhamnolipid biosynthesis operon
rhlAB and hydrogen cyanide production by hcnABC [73], known con-
tributors to in vivo P. aeruginosa competitiveness and also absent in
isolate HB13. Moreover, mutations in rhRI systems are correlated to
increased denitrification activity and therefore anaerobic growth in P.
aeruginosa PAO1 [74]. Since reduced oxygen concentrations and
anaerobiosis are frequently associated with lung environment and
biofilm growth [75], rhlRI-deficiency would be beneficial for a chronic
persistent strain. Isolate HB13 was able to establish lung infection in a
pneumonia-diagnosed patient. Deletions of rhlRI-related operons might
have occurred, driven by selective evolution during lung colonization.
Absence of hcnABC [76] and rhlAB [77] clusters, deletions of rhlR or rhlI
[78] have been described, particularly in persistent infections and with
reported attenuated virulence. To our knowledge, this is the first report
of a clinical isolate not carrying these three clusters.
SNVs and indels did not occur evenly spread through the genome of
both isolates, suggesting that some genetic loci are highly conserved
while others are hotspots, prone to variations that might translate into
niche-specific adaptations or isolate-specific characteristics, thus par-
tially constituting the molecular basis for the registered phenotypic
variations.
Our in silico analysis supported the phenotypic characterization of
both P. aeruginosa isolates, corroborating the PDR and avirulent phe-
notype of isolate HB13, and the pan-susceptible and higher virulent
potential of isolate HB15. This strategy allowed the identification of P.
aeruginosa putative novel determinants among the signatures features
of both isolates, that would otherwise be ignored, making whole-
genome sequencing a more unbiased and consistent method for de-
termining the genetic potential for antibiotic resistance and virulence.
Moreover, we found a set of, apparently, secreted proteins with pre-
viously unknown or putative function and our analysis suggests an in-
volvement in P. aeruginosa pathogenesis. For instance, homology search
of the peptidase secreted by isolate HB15 (Supplementary Fig. S1)
showed that it is widespread in Pseudomonas aeruginosa and other
human pathogens, as the Gram-negative Acinetobacter baumannii and
Enterobacter cloacae, but also Gram-positive bacteria as Streptococcus
pneumoniae, often found in co-inhabitation with Pseudomonas aerugi-
nosa [79,80], suggesting a HGT phenomenon. Homologous hits were
also found in environmental bacteria, which does not discard a pepti-
dase virulence-association, as some environmental strains are known
plant pathogens with reported ability to infect humans [81]. Con-
sidering survival and adaptation of bacteria in humans similar to the
one in the environment, pathogenicity determinants will also be present
in non-pathogens. Future work should focus on characterization of the
molecular activity of these secreted proteins with previously unknown
or putative function as novel antibiotic resistance and virulence
determinants.
Given the multifactorial and combinatorial nature of P. aeruginosa
pathogenicity [41], secretion of more virulence factors by P. aeruginosa
HB15 together with other observed phenotypic traits and cytotoxic data
(data not shown), corroborate former in silico predictions of distinctive
virulent behaviors for isolates HB13 and HB15. Active prophages,
proteases and peptidases possibly play a determinant role in its mod-
ulation, particularly in the latter isolate.
5. Conclusion
Associating clinical outcome with phenotype and genotype is im-
perative to aid clinicians in treatment and eradication of bacterial in-
fections, towards a more efficient and tailored approach to tackle iso-
late-specific singularity. Epidemiological, genotyping and phenotyping
follow-up studies are required to verify the consequences of the clinical
approach. Complementary diagnostic tests are crucial to guide clin-
icians to choose therapeutic strategies more appropriately, based not
only on species identification and antibiotic resistance profiles but also
in molecular patterns of detected pathogens. However, evaluating the
genotypic profile might not provide the necessary information to ac-
count for a phenotype. In summary, as showed in this study, linking P.
aeruginosa genomic repertoire to a phenotypic profile is a necessary
aspect of uncovering novel pathogenic mechanisms and understanding
the relative contribution of known determinants and their allelic var-
iants.
Expanding this approach to other P. aeruginosa clinical isolates
would aid in the creation of a variations profile and evolutionary
strategies, correlating their genomic repertoire to a phenotypic profile.
Combining available pipelines with the ever increasing –omics data will
lead to a better prioritization strategy where the most promising de-
terminants can be rapidly targeted for future analysis, aimed at better
understanding P. aeruginosa pathogenesis. Integration of this data with
the clinical outcome will deliver a solid description of the pathogen
performance. This would rouse the establishment of a bacteriological,
genome typing-like, tool that may help in diagnostic of Pseudomonas
aeruginosa strains and in prognostic, giving the possibility to provide a
customized antimicrobial treatment.
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